Ann: Unmarketable Parcel Share Sale Facility, page-39

Sorry BT...I have to disagree with you

Have a look around mate....practically every biotech on the market has substantially re-rated...biotechs behind DXB in terms if trials..CYP, PAB, ACW, BXN and the list goes on

And DXB has still managed to attract zero interest, zero volume and zero tangible rise in value

How you and others can see this as the '' dream team'' and '' a management team for which we should feel blessed'' absolutely amazes me....it flies in the face of every bit of tangible evidence we have

They have had plenty of time....my report card is a '' Fail''